In 1981 /82 we have reported that urinary neopterin concentrations were increased with high frequency in patients with haematological neoplasias. Seven years after this first report we have investigated whether the magnitude of the measured neopterin increase was associated with the subsequent survival of these patients . Complete clinical follow up data were available of 85 out of 115 patients initially investigated in this study. Overall, Kaplan-Meier analyses show that patients with Hodgkin's disease had the best prognosis compared to patients with non-Hodgkin' s lymphoma and chronic myelogenous leukaemia. Hodgkin's patients had, on average, also lower urinary neopterin levels than the other patients. Higher neopterin concentrations were associated with worse prognosis in patients with Hodgkin's disease (p = 0.04, Breslow test) and with nonHodgkin's lymphoma (p = 0.035). In patients with chronic myelogenous leukaemia survival probability was lower in patients with higher neopterin concentrations 2 years after neopterin measurement (p < 0.01). Later on, no difference of survival was obsen·ed. ~larkediy decreasing survival was seen after an observation period longer than 4 years in both groups. \.lulti\ariate analyses show that the predictive value of neopterin concentrations was independent from stage of di sease. We conclude that Jleopterin concentrations are of predictive relevance in patients with haematologic ne opiasias.
Introduction
Neopterin, a pyrazino-(2,3-d)-pyrimidine derivative, originates from guanosine triphosphate (GTP) and is secreted by human macrophages which have been exposed to interferon-(IFN)-gamma (1) . Neopterin measurement provides a means to assess the activation state of the T cell/macrophage system (2) . In several malignant disorders, e. g., cancer of the uterine cervix (3), prostatic carcinoma (4), ovarian cancer (5) and lung cancer (6) , neopterin concentrations have been proved to be of prognostic relevance: raised concentrations at the time of diagnosis were associated with an increased risk of death due to the disease.
Increased neopterin concentrations were reported from patients with haematological neoplasias (7 -9) . In this study we evaluated the predictive value of 
Patients and Methods

a ) Patients
In 1981, neopterin concentrations were measured in 115 patients with haematological neoplasias (7, 8) . Clinical follow-up was evaluable in 85 (74%) of these patients. Mean observation time was 68 months (range 4 -89). Clinical data were analyzed from 38 patients with HD, 36 with NHL, including 17 patients with chronic lymphocytic leukaemia (CLL), and from 11 patients with CML. Basic characteristics of patients are summarized in Table 1 .
Oenz et at.: Urinary neoptcrin as a prognostic factor in haematological neoplasias Similarly to HD, staging of NHL was generally made according to the ANN Arbor classification, with the exception of CLL, where the Rai classification was used (12) . For the assessment of the entire group, patients were divided into two categories: "early stage" was defined as stages 1/11 according to the Ann Arbor classification and stages 0/1/11 according to the Rai classification. Stages III/IV of both classifications were equally judged as "advanced stage".
In patients with NHL the mean value of urinary neopterin was significantly raised. Neopterin concentrations were higher than in HD patients. In contrast to the findings in HD there was a correlation between neopterin concentrations and the stage of the disease, advanced stage patients showing higher concentrations than patients with earlier stages. In CLL patients neopterin values were quite comparable to those in patients with other NHL entities.
Chronic myelogenous leukaemia
The third group comprised 11 patients with CML. All of them were in chronic phase of the disease at the time when neopterin concentrations were measured. Patients with CML showed raised neopterin concentrations compared to healthy subjects. The mean value was within the same range as that in NHL, but significantly higher than in HD patients (Table 1) .
b) Neopterin measurement
Urinary neopterin was determined by an optimized and fully automated high pressure liquid chromatography technique (HPLC) without previous oxidative treatment as described elsewhere (13, 14) . By this reverse-phase technique, urinary creatinine is simultaneously determined in the same urine specimen. Neopterin concentrations are expressed as ~mol neopterin/mol creatinine.
c) Statistical procedures
The Kruskal-Wallis-test was used to assess a dependence of neopterin concentrations on tumour stage. Survival functions were constructed according to the product-limit method (15) , the dates of urine collection were used as starting point. The patients were dichotomized using the mean neopterin concentrations of each tumour group for further analysis.
Differences of survival functions between patients with low and high neopterin concentrations were tested by the generalized Wilcoxon test (16) . Multivariate analyses according to the Proportional Hazards model were performed in order to investigate the prognostic effect of one or more variables (17) . For the possible nonproportional effect of the type of disease on the base-line survival curves, a stratification procedure was employed (18) .
The role of raised neopterin as a risk factor independent from other variables was defined using a multivariate analysis. We used again the mean values as disease-specific "cut-off-Ievels". Values above these levels were judged as "high", those below as "low" levels. HD and NHL patients were analyzed together since in both groups patients with early stage and advanced stage could be evaluated. However, the type of the tumour was used as a stratification variable for the subsequent analysis.
Results
In Figure 1 A the overall survival of the three groups of patients (HD, NHL, CML) is graphically demonstrated. As expected, patients with HD show the best prognosis, more than 80% of patient being alive after 7 years. In NHL patients survival probability was about 60% after 7 years. CML patients had a median survival time of 4.5 years.
Hodgkin's disease
Within the observation time 6/38 patients (16%) died due to the disease. All of the six patients who died had advanced stage of disease and were treated at the time of neopterin measurement. Neopterin concentrations were significantly elevated in these patients compared with HD patients still being alive. This holds true even when only patients with advanced stage disease are compared. Survival probability was significantly lower in patients showing neopterin concentrations above the mean value (Fig. 1 B) .
Non-Hodgkin's lymphomas
Survival probability of NHL patients (Fig. 1A) was lower in patients with advanced stage disease (p < 0.0t). Patients with neopterin concentrations exceeding the mean value of NHL patients (547 !lmol / mol creatinine) had a significantly increased risk of death due to the disease (Fig. 1 C) . Similarly to the findings in HD patients, neopterin concentrations were of prognostic relevance in addition to the stage of disease. Out of the 36 patients with NHL 32 (89%) had NHL of low malignancy according to the Kiel classification, only 4/36 (11 %) suffered from NHL of high malignancy. Two of these 4 patients died from their disease, both had highly raised neopterin concentrations (1256 and 927 !lmol/mol creatinine, respectively).
Chronic myelogenous leukaemia
Again, survival was better in patients with lower urinary neopterin concentrations, the difference was, however, not significant (p > 0.05), probably intluenced by the lenght of the study. Markedly decreasing suryi\al was observed in the group of patients with 10\\ neopterin after an observation period longer than -+ years (Fig. 10) . The survival probability 2 years after neopterin measurement was significantly higher in patients with lower neopterin concentrations
A multivariate analysis of survival in patients with HD and NHL, stratified by the tumour type, revealed that high neopterin levels remained prognostically significant in addition to tumour stage. This is demonstrated by the regression coefficients shown in Table 2 . 
Discussion
The majority of patients suffering from haematological neoplasias shows raised concentrations of urinary neopterin (7, 9) . Mean values in our patients differed from one disease to another. Nevertheless, elevation exceeding the disease specific mean value represents a certain risk factor. The increased risk of death due to the disease defined by raised neopterin concentrations was established in all patients groups. It is independent of other known unfavourable signs, e. g. , advanced stage or presence of B symptoms.
Because of this prognostic relevance therapeutic consequences may be considered. Concerning HD, future clinical trials might take neopterin measurements into account, when a decision for either chemotherapy or radiotherapy or even combined therapy has to be made. This is of special interest in stage III patients.
Additionally it could influence the duration of therapy. In NHL patients neopterin concentrations might heip to define groups of high risk, e. g., patients for whom a more aggressive treatment would be indicated to improve therapeutic results. To answer these questions, prospective studies are required. However, recent data by others confirm the prognostic relevance of urinary neopterin in NHL patients (9) . For CML the number of patients is too small to draw firm conclusions.
It remains to be shown if an increase of neopterin concentrations precedes the development of blast crisis or relapse after bone marrow transplantation , or if elevated neopterin correlates with other risk factors , e. g. , lack of Philadelphia chromosome or multiple cytogenetic abnormalities.
The fact, that in haematologic neoplasias, but also in various solid tumours, elevated neopterin -recognized as a sign for a stimulation of the cell mediated immune system -correlates with a worse prognosis, may seem surprising at first glance. A possible explanation for permanently elevated neopterin concentrations might be the presence of antigenic structures recognized by the immune system. Immunologic activation was further confirmed by the detection of increased concentrations of circulating IFN gamma in patients with haematological neoplasias (19) . The finding of activated immune cells obviously contrasts defective in vitro responses of immune cells. There is some discussion of the biological significance of activated compartments of the immune system in the development of malignant tumours (20) . Whether activated macrophages may induce endogenous immunosuppression or may even promote tumour cell growth by secreting various growth factors (21) remains open. Activated macro phages have been definitely shown to promote angiogenesis which might of course he of uppermost importance for a growing bulky tumour mass (22) .
Pteridines / Vol. 1 / 1989 I N o . ."\ Summarizing the results, our data show, that urinary neopterin concentrations are of prognostic relevance in haematologic neoplasias. We believe that measurement of neopterin in tumour patients might also contribute to better understanding of the complex interactions between tumour and host.
